PentixaPharm GmbH

VISION
PentixaPharm is committed to developing the innovative theranostic pair PentixaFor and PentixaTher. PentixaFor and PentixaTher are two-small peptide-based radiopharmaceuticals which specifically target the CXCR4-receptor expressed in most fast progressing diseases such as hematological and solid cancers as well as cardiovascular malignancies.
 
MANAGEMENT TEAM
With a solid history of building successful radiopharmaceutical start-ups, the PentixaPharm management  team incorporates personal experience in all key functions of an early stage radiopharmaceutical development  company: clinical development, manufacturing as well as organizational and financial set-up.